App-Quantinova.ai

Breast cancer histology and non-sentinel lymph node involvement following a positive sentinel lymph node biopsy: A multi-institutional cohort study.

Alana Hosein - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Management of lobular carcinoma in situ: A decision analysis.

Stephanie M Wong - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Correlation between progression free survival and overall survival in patients with metastatic breast cancer receiving anthracyclines, taxanes or targeted therapies: A trial level meta-analysis.

Georges Adunlin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

taxane

Analysis of BRCA1-related functional associations in sporadic triple negative breast cancer: A network-based approach.

Arcangela De Nicolo - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

N/A

A phase Ib/II study of cancer stemness inhibitor napabucasin (BB608) combined with weekly paclitaxel in advanced triple-negative breast cancer.

Carlos Becerra - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

Napabucasin

Cancer susceptibility mutations in individuals with breast and ovarian cancer using next-generation sequencing.

Kenneth Offit - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Ovarian cancer

N/A

Incidental germline findings identified in a somatic genomic sequencing program for advanced cancer patients.

Neda Stjepanovic - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

TP53

Variation in protein-coding sequence and the genetic basis of cisplatin-induced toxicities among testicular cancer survivors (TCS) in the Platinum Study.

Eric R Gamazon - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Peripheral neuropathy

Cisplatin

Meta-analysis of hepatocellular carcinoma incidence in patients who have obtained a sustained virologic response after antiviral therapy for hepatitis C.

Ali Hosni - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Liver cancer

N/A

The cardiovascular safety of aromatase inhibitors and tamoxifen in post-menopausal women with breast cancer: A systematic review and meta-analysis of randomized controlled trials.

Farzin Khosrow-Khavar - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Tamoxifen

Circulating tumor DNA mutational profiling by targeted next generation sequencing guides personalized treatments in multiple cancer types.

Yang Shao - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Genotype concordance between archival tumor DNA (atDNA) and circulating tumor DNA (ctDNA) in advanced solid malignancies: The Oncopanel Pilot study.

Hagen F. Kennecke - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Treatment decision making and psychosocial outcomes associated with rapid genetic testing for BRCA1 and BRCA2 in women newly diagnosed with breast cancer.

Kelly A. Metcalfe - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Baseline plasma matrix metalloproteinase 9 (MMP9) to predict overall survival (OS) benefit from bevacizumab (BEV) in newly diagnosed glioblastoma (GBM): Retrospective analysis of AVAglio.

Olivier L. Chinot - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Bevacizumab

Residual tumor volume and change in tumor volume during adjuvant therapy to predict long-term survival in AVAglio: Phase 3 newly diagnosed glioblastoma patients treated with radiation, temozolomide, and bevacizumab or placebo.

Benjamin M. Ellingson - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Temozolomide

Comparison of oncometabolite 2-hydroxyglutarate (2HG) levels in mutant isocitrate dehydrogenase (IDH) versus wild-type (WT) glioma tissues.

Hao-Wen Sim - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Brain cancer

N/A

Phase 1, multicenter, open-label, dose-escalation, study of marizomib (MRZ) and bevacizumab (BEV) in WHO grade IV malignant glioma (G4 MG).

Daniela Annenelie Bota - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gliomas

Bevacizumab

Radiologic progression types are treatment specific: An exploratory analysis of a phase 3 study of bevacizumab plus radiotherapy plus temozolomide for patients with newly diagnosed glioblastoma (AVAglio).

Martha Nowosielski - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Temozolomide

Genetic landscape of extreme responders with anaplastic oligodendroglioma: NRG Oncology/RTOG 9402.

Matthias Holdhoff - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Anaplastic oligodendroglial tumors

N/A

Overall survival in patients with glioblastoma before and after bevacizumab approval.

Derek Richard Johnson - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Bevacizumab

Filters

28841 Abstracts